PhaseBio Pharmaceuticals, Inc. (PHAS) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Malvern, PA, United States. Le PDG actuel est Jonathan Mow.
PHAS a date d'introduction en bourse 2018-10-18, 60 employés à temps plein, cotée sur le NASDAQ Global Market.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
